Management of Increased Anxiety in Patients Stabilized on Lithium

Initial Assessment and Monitoring

The American Academy of Family Physicians recommends verifying current lithium levels to ensure they remain in the therapeutic range of 0.2-0.6 mEq/L, as levels outside this range could contribute to anxiety symptoms 1

The American Academy of Family Physicians suggests starting buspirone 5 mg twice daily, which can be increased to a maximum of 20 mg three times daily, for mild-to-moderate anxiety in patients already on mood stabilizers 1
The American Academy of Family Physicians recommends sertraline as the preferred SSRI due to fewer effects on metabolism of other medications, starting at 25-50 mg daily up to 200 mg daily, for more severe anxiety or anxiety accompanied by depressive features 1
The National Comprehensive Cancer Network recommends lorazepam, oxazepam, or temazepam as preferred benzodiazepines for acute or severe anxiety, with short half-lives and minimal accumulation issues 1
The National Comprehensive Cancer Network suggests alprazolam 0.25-0.5 mg orally three times daily, with elderly patients starting at 0.25 mg two or three times daily, for acute or severe anxiety 2, 3
The National Comprehensive Cancer Network warns that elderly patients are especially sensitive to benzodiazepine effects, requiring careful dosing and monitoring 2, 3

The American Academy of Child and Adolescent Psychiatry recommends lithium as the first-line mood stabilizer for patients with bipolar disorder and anxiety 4
Baseline and ongoing monitoring should include thyroid function, as lithium-induced hypothyroidism could present with anxiety-like symptoms 5
Lithium levels should be checked twice weekly during the acute phase until stabilized, and monitoring should continue every 3-6 months once stable 6
Monitoring for signs of toxicity (confusion, tremor, ataxia) that could mimic anxiety is crucial 6
Patients on lithium therapy should avoid NSAIDs and ensure adequate hydration to prevent toxicity 6

The American Academy of Child and Adolescent Psychiatry recommends obtaining baseline complete blood count, thyroid function tests, urinalysis, blood urea nitrogen, creatinine, serum calcium levels, and pregnancy test in females before initiating lithium therapy, and monitoring lithium levels, renal and thyroid function every 3-6 months to detect and prevent complications 7
Complete blood cell counts, thyroid function tests, urinalysis, blood urea nitrogen, creatinine, serum calcium levels, and pregnancy testing in adolescent females must be obtained before starting lithium, as recommended by the American Academy of Child and Adolescent Psychiatry 7

Weight monitoring remains important while on lithium therapy, and lifestyle interventions and dietary counseling should be considered, as recommended by the American Academy of Child and Adolescent Psychiatry 7

The American Academy of Child and Adolescent Psychiatry recommends continuing lithium for at least 12-24 months after stabilization of acute episodes 7
For bipolar disorder maintenance, lithium should be continued for at least 2 years after the last episode, according to PLoS Medicine 8
Decisions to continue lithium beyond 2 years should involve mental health specialists, as suggested by PLoS Medicine 8
The American Academy of Child and Adolescent Psychiatry recommends balancing the deleterious impact of symptom recurrence versus medication side effects when considering discontinuation of lithium 7
Any discontinuation attempts of lithium should be gradual with close monitoring for relapse, as recommended by the American Academy of Child and Adolescent Psychiatry 7, 9

The American Academy of Child and Adolescent Psychiatry recommends gradual retitration of lithium after a one-week interruption to avoid toxicity and ensure therapeutic monitoring, as abrupt discontinuation followed by full-dose restart increases the risk of both rebound mania and neurotoxicity 10

The patient should start at a reduced dose, typically 50-75% of the previous maintenance dose, and retitrate based on clinical response and serum levels, with a target therapeutic range of 0.6-1.2 mEq/L for acute treatment 10